NKCC

Home Transmembrane Transporters NKCC

NKCC Products

  • All (6)
  • NKCC Inhibitors (5)
  • New NKCC Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8615 DCA (Sodium dichloroacetate) DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
bioRxiv, 2025, 2025.04.03.647023
bioRxiv, 2025, 2025.08.24.671623
bioRxiv, 2025, 2023.08.11.552890
S1603 Furosemide Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
J Immunother Cancer, 2024, 12(11)e009805
Ren Fail, 2022, 44(1):1345-1355
Environ Toxicol Chem, 2021, 10.1002/etc.5018
S1287 Bumetanide Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
J Immunother Cancer, 2024, 12(11)e009805
PLoS Pathog, 2024, 20(10):e1012601
Cancer Med, 2024, 13(11):e7291
S5194 Furosemide sodium Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.
Nat Commun, 2024, 15(1):7342
Ren Fail, 2022, 44(1):1345-1355
F1486 NKCC1 Antibody [H4B9]
E2358 Azosemide Azosemide is a potent Na+–K+–2Cl− cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.
S8615 DCA (Sodium dichloroacetate) DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
bioRxiv, 2025, 2025.04.03.647023
bioRxiv, 2025, 2025.08.24.671623
bioRxiv, 2025, 2023.08.11.552890
S1603 Furosemide Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
J Immunother Cancer, 2024, 12(11)e009805
Ren Fail, 2022, 44(1):1345-1355
Environ Toxicol Chem, 2021, 10.1002/etc.5018
S1287 Bumetanide Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
J Immunother Cancer, 2024, 12(11)e009805
PLoS Pathog, 2024, 20(10):e1012601
Cancer Med, 2024, 13(11):e7291
S5194 Furosemide sodium Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.
Nat Commun, 2024, 15(1):7342
Ren Fail, 2022, 44(1):1345-1355
E2358 Azosemide Azosemide is a potent Na+–K+–2Cl− cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.

Choose Selective NKCC Inhibitors